Alexander Schwartz
Partner @ XISTA Science Ventures
Vienna, Austria
Alexander Schwartz is a pre-seed investor at XISTA Science Ventures in Vienna focused on Biotechnology and Energy. Alexander Schwartz is based out of Vienna, Wien, and is the Board Director of VALANX Biotech. Alexander previously worked at ARACON Consulting as a Partner. Alexander Schwartz attended the University of Vienna.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 69%
Last updated:
For AI agents: llms.txt
Industries Alexander Schwartz invests in
Stages Alexander Schwartz invests in
Countries Alexander Schwartz invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (23%)
- Energy 1 (8%)
- Battery 1 (8%)
- Medical 1 (8%)
- Health Care 1 (8%)
Stage
- Pre-Seed 3 (23%)
- Seed 2 (15%)
- Series A 1 (8%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rivus is a start-up that serves as the commercialization platform for the aqueous organic flow battery technology. | $2.3M / Seed / Jul 10, 2026 | ||
| Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity. | $2.3M / Pre-Seed / Jun 30, 2026 | ||
| Invisible Light Labs uses Fourier transform infrared (FTIR) spectroscopy and nanoelectromechanical sensing technologies to enable chemical analysis of materials and nanomaterials that are available in minuscule amounts in a variety of industries, from environmental monitoring to pharmaceuticals. | $1.7M / Pre-Seed / Jun 09, 2026 | ||
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $3.5M / Venture - Series Unknown / Mar 12, 2026 | ||
| Rivus is a start-up that serves as the commercialization platform for the aqueous organic flow battery technology. | $566.7K / Seed / Dec 05, 2023 | ||
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $2.5M / Seed / Nov 07, 2023 | ||
| CellEctric is building the bridge between electrodynamics and biology. We believe that electrodynamic cell manipulation will make routine life science applications faster, easier, and more precise.By combining cutting-edge developments in material science, electrical engineering, and biotechnology, CellEctric is committed to shaping a better,healthier future for all.Founded in early 2021, we are currently developing a platform that transforms complex samples into simple, single-population solutions. Our current showcase is the isolation of viable bacteria from human samples toward greatly accelerated sepsis diagnosis. The future pipeline is filled with proof-of-concept applications such as the isolation of leukocytes from human whole-blood, toward a customizable platform that separates increasingly similar mammalian cell populations at high throughput.Fast, automated, and selective. | Pre-Seed / Feb 21, 2022 | ||
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | Seed / May 14, 2020 | ||
| G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply. | Series A / May 08, 2020 | ||
| G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply. | $548.4K / Pre-Seed / May 08, 2020 | ||
| See all 13 investments → | |||
Co-Investors
About XISTA Science Ventures
We invest in biotech and deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We are embedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
XISTA Science Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexander Fischl
Tech Transfer Associate
|
|||
|
Alexander Schwartz
Partner
|
|||
Markus Wanko
Founder and Managing Partner
|
|||
Stephan Huber
Venture Partner
|
|||
Bernhard Petermeier
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexander Schwartz invest in?
Alexander Schwartz invests primarily in Biotechnology, Energy and Battery startups, most often at Pre-Seed and Seed stage. Most of the 13 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexander Schwartz?
Public channels for Alexander Schwartz include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexander Schwartz last invest?
The most recent investment recorded for Alexander Schwartz closed in Jul 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
